HomeCompareTRGNF vs PLD

TRGNF vs PLD: Dividend Comparison 2026

TRGNF yields 200.00% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRGNF wins by $112.86M in total portfolio value
10 years
TRGNF
TRGNF
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full TRGNF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — TRGNF vs PLD

📍 TRGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRGNFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRGNF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRGNF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRGNF
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, TRGNF beats the other by $46,681,711.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRGNF + PLD for your $10,000?

TRGNF: 50%PLD: 50%
100% PLD50/50100% TRGNF
Portfolio after 10yr
$62.93M
Annual income
$32,716,266.23/yr
Blended yield
51.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

TRGNF
No analyst data
Altman Z
2.5
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRGNF buys
0
PLD buys
0
No recent congressional trades found for TRGNF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRGNFPLD
Forward yield200.00%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$119.36M$6.50M
Annual income after 10y$60,176,096.29$5,256,436.18
Total dividends collected$112.49M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRGNF vs PLD ($10,000, DRIP)

YearTRGNF PortfolioTRGNF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$30,700$20,000.00$11,255$555.24+$19.4KTRGNF
2$90,232$57,383.18$13,062$1,018.59+$77.2KTRGNF
3$254,173$157,624.56$15,903$1,926.67+$238.3KTRGNF
4$686,927$414,961.74$20,839$3,823.32+$666.1KTRGNF
5$1,783,118$1,048,106.39$30,464$8,166.08+$1.75MTRGNF
6$4,450,613$2,542,677.12$52,054$19,457.30+$4.40MTRGNF
7$10,693,420$5,931,263.38$109,886$54,188.93+$10.58MTRGNF
8$24,760,608$13,318,648.86$304,030$186,451.18+$24.46MTRGNF
9$55,315,649$28,821,798.66$1,166,125$840,813.32+$54.15MTRGNF
10$119,363,841$60,176,096.29$6,504,190$5,256,436.18+$112.86MTRGNF

TRGNF vs PLD: Complete Analysis 2026

TRGNFStock

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Full TRGNF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this TRGNF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRGNF vs SCHDTRGNF vs JEPITRGNF vs OTRGNF vs KOTRGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.